Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-29
2011-03-29
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07915222
ABSTRACT:
The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
REFERENCES:
patent: 5434131 (1995-07-01), Brady et al.
patent: 5521288 (1996-05-01), Brady et al.
patent: 5580756 (1996-12-01), Brady et al.
patent: 5770197 (1998-06-01), Brady et al.
patent: 5773253 (1998-06-01), Ledbetter et al.
patent: 5844095 (1998-12-01), Brady et al.
patent: 5851795 (1998-12-01), Brady et al.
patent: 5885579 (1999-03-01), Brady et al.
patent: 5885796 (1999-03-01), Brady et al.
patent: 5916560 (1999-06-01), Aruffo et al.
patent: 5968510 (1999-10-01), Brady et al.
patent: 5977318 (1999-11-01), Brady et al.
patent: 6090914 (2000-07-01), Brady et al.
patent: 6641809 (2003-11-01), Brady et al.
patent: 6830937 (2004-12-01), Brady et al.
patent: 7094874 (2006-08-01), Peach et al.
patent: 7304033 (2007-12-01), Larsen et al.
patent: 7307064 (2007-12-01), Rusnak
patent: 7332303 (2008-02-01), Schilling et al.
patent: 7455835 (2008-11-01), Cohen et al.
patent: 7528111 (2009-05-01), Vratsanos et al.
patent: 7541164 (2009-06-01), Schilling et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Todderud et al.
patent: 2003/0007968 (2003-01-01), Adams et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 2005/0019859 (2005-01-01), Schilling et al.
patent: WO2007/076032 (2007-07-01), None
patent: WO2007/076354 (2007-07-01), None
American Thoracic Society, “Diagnostic Standards and Classification of Tuberculosis in Adults and Children”, Am J Respir Crit Care Med., vol. 161, pp. 1376-1395 (2000).
American Thoracic Society, “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection”, Am J Respir Crit Care Med., vol. 161, pp. S221-S247 (2000).
Balsa, A. et al., “Differential Expression of the Costimulatory Molecules B7.1(CD80) and B7.2 (CD86) in Rheumatoid Synovial Tissue”, British Journal of Rheumatology, vol. 35, pp. 33-37 (1996).
Birrell, F.N. et al., “How does the Short Form 36 Health Questionnaire (SF-36) in Rheumatoid Arthritis (RA) Relate to RA Outcome Measures and SF-36 Population Values? A Cross-Sectional Study”, Clin Rheumatol, vol. 19, pp. 195-199 (2000).
Broach, J., “Construction of High Copy Yeast Vectors Using 2-μm Circle Sequences”, Methods in Enzymology, vol. 101, pp. 307-325 (1983).
Clarke, L. et al., “Selection Procedure for Isolation of Centromere DNAs fromSaccharomyces cerevisiae”, Methods in Enzymology, vol. 101, pp. 300-306 (1983).
Cohen, S. et al., “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA”, PNAS, vol. 69(8), pp. 2110-2114 (1972).
Cush, J. et al., “Phenotypic Analysis of Synovial Tissue and Peripheral Blood Lymphocytes Isolated from Patients with Rheumatoid Arthritis”, Arthritis and Rheumatism, vol. 31(10), pp. 1230-1238 (1988).
Emery, P., “The Optimal Management of Early Rheumatoid Disease: The Key to Preventing Disability”, British Journal of Rheumatology, vol. 33, pp. 765-768 (1994).
Felson, D. et al., “The American College of Rheumatology Preliminary Core Set of Disease Activity Measures for Rheumatoid Arthritis Clinical Trials”, Arthritis and Rheumatism, vol. 36(6), pp. 729-740 (1993).
Fiers, W. et al., “Complete nucleotide sequence of SV40 DNA”, Nature, vol. 273, pp. 113-120 (1978).
Firestein, G. et al., “Quantitative Analysis of Cytokine Gene Expression in Rheumatoid Arthritis”, The J. of Immunology, vol. 144, pp. 3347-3353 (1990).
Firestein, G et al., “How Important are T Cells in Chronic Rheumatoid Synovitis?”, Arthritis and Rheumatism, vol. 33(6), pp. 768-773 (1990).
Førre, Ø. et al., “Augmented Numbers of HLA-DR-Positive T Lymphocytes in the Synovial Fluid and Synovial Tissue of Patients with Rheumatoid Arthritis and Juvenile Rheumatoid Arthritis”, Scand. J. Immunol., vol. 15, pp. 227-231 (1982).
Fries, J. et al., “Measurement of Patient Outcome in Arthritis”, Arthritis & Rheumatism, vol. 23(2), pp. 137-145 (1980).
Fries, J. et al., “The Dimensions of Health Outcomes: The Health Assessment Questionnaire, Disability & Pain Scales”, The J. of Rheumatology, vol. 9(5), pp. 789-793 (1982).
Furst, D E. et al., “Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents”, Ann Rheum Dis., vol. 61, pp. 62-63 (2002).
Goeddel, D. et al., “Synthesis of human fibroblast interferon byE. coli”, Nucleic Acids Research, vol. 8(18), pp. 4057-4074 (1980).
Harrison, B.J. et al., “Natural Remission in Inflammatory Polyarthritis: Issues of Definition and Prediction”, British J of Rheumatology, vol. 35, pp. 1096-1100 (1996).
Hess, B. et al., “Cooperation of Glycolytic Enzymes”, J. Adv. Enzyme Reg., vol. 7, pp. 149-167 (1968).
Hitzeman, R. et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique”, The J. of Biological Chemistry, vol. 255(2), pp. 12073-12080 (1980).
Hochberg,M. et al., “Epidemiology of Rheumatoid Arthritis: Update”, Epidemiologic Reviews, vol. 12, pp. 247-252 (1990).
Holland, M. et al., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase”, Biochemistry, vol. 17(23), pp. 4900-4907 (1978).
Karin, M. et al., “Human metallothionein genes-primary structure of the metallothionein-II gene and a related processed gene”, Nature, vol. 299, pp. 797-802 (1982).
Keller, S. et al., “The SF-36 Arthritis-Specific Health Index (ASHI)”, Medical Care, vol. 37(5), pp. MS51-MS60 Supplement (1999).
Kidd, B L. et al., “Immunohistological features of synovitis in ankylosing spondylitis: a comparison with rheumatoid arthritis”, Ann Rheum Dis., vol. 48, pp. 92-98 (1989).
Klareskog, L. et al., “Relationships between HLA-DR-expressing Cells and T Lymphocytes of Different Subsets in Rheumatoid Synovial Tissue”, Scand. J. Immunol., vol. 15, pp. 501-507 (1982).
Kolhekar, A. et al., “Peptidylglycine-Hydroxylating Monooxygenase: Active Site Residues, Disulfide Linkages, and a Two-Domain Model of the Catalytic Core”, Biochemistry, vol. 36(36), pp. 10901-10909 (1997).
Konttinen, Y. et al., “Characterization of the Immunocompetent Cells of Rheumatoid Synovium from Tissue Sections and Eluates”, Arthritis & Rheumatism, vol. 24(1), pp. 71-79 (1981).
Kosinski, M. et al., “The SF-36 Health Survey as a Generic Outcome Measure in Clinical Trials of Patients with Osteoarthritis and Rheumatoid Arthritis”, Medical Care, vol. 37(5), pp. MS23-MS39 Supplement (1999).
Laffon, A. et al., “Upregulated Expression and Function of VLA-4 Fibronectin Receptors on Human Activated T Cells in Rheumatoid Arthritis”, J. Clin. Invest., vol. 88, pp. 546-552 (1991).
Liu, M. et al., “The Presence of Costimulatory Molecules CD86 and CD28 in Rheumatoid Arthritis Synovium”, Arthritis & Rheumatism, vol. 39(1), pp. 110-114 (1996).
Markenson, J.A., “Worldwide Trends in the Socioeconomic Impact and Long-Term Prognosis of Rheumatoid Arthritis”, Seminars in Arthritis and Rheumatism, vol. 21(2), pp. 4-12 (1991).
McGonagle, D. et al., “The Relationship between Synovitis and Bone Changes in Early Untreated Rheumatoid Arthritis”, Arthritis & Rheumatism, vol. 42(8), pp. 1706-1711 (1999).
Østergaard, M.
Becker Jean-Claude
Corbo Michael
Vratsanos George
Bristol--Myers Squibb Company
Ouspenski Ilia
Parlet Nickki L.
LandOfFree
Method of preventing the development of rheumatoid arthritis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing the development of rheumatoid arthritis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing the development of rheumatoid arthritis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648630